Abstract
A phase II trial of esorubicin (4′ deoxydoxorubicin) was performed in patients with cancers of the breast, colon, kidney, lung and melanoma. Two partial responses were observed out of 16 patients with breast cancer treated with esorubicin. No objective responses (complete or partial) were seen in patients with colon cancer (18 patients), lung cancer (12 patients), renal cell cancer (12 patients) and melanoma (18 patients). Myelosuppression was the most significant toxicity encountered with granulocytopenia (neutrophils < 1,000) observed in 38% of patients. As discussed, we feel that further investigation of esorubicin in anthracyclinesensitive tumors is warranted.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Salmon SE, Young L, Soehnlen B, Liu R: Antitumor activity of esorubicin in human tumor clonogenic assay with comparisons to doxorubicin. J Clin Oncol 2(4):282–286, 1984
Casazza AM: Experimental evaluation of anthracycline analogs. Cancer Treat Rep 63:835–844, 1979
Garewal HS, Robertone A, Salmon SE, Jones SE, Alberts DS, Brooks R: Phase I trial of esorubicin (4′deoxydoxorubicin). J Clin Oncol 2:1034–1039, 1984
Cohen J: Statistical power analysis for the behavioral sciences. Academic Press, 1977
Bonfante V, Rossi A, Brambilla C, Ferrari L, Villani F, Comazzi R, Crippa F, Monfardini S, Bonadonna G: Comparative activity and toxicity of adriamycin and new anthracycline analogs in advanced breast cancer. Proc Am Assoc Cancer Res 26:165, 1985
Leitner SP, Casper ES, Hakes TB, Kaufman RJ, Winn RJ, Scoppetuolo M, Raymond V, Geller NL, Young CW: Phase II trial of 4′-deoxydoxorubicin in patients with advanced breast cancer. Cancer Treat Rep 69(11):1319–1320, 1985
Blum RH, Carter SK: Adriamycin: A new anticancer drug with significant clinical activity. Ann Int Med 80:249–259, 1974
Jones SE, Dean JC, Young L, Salmon SE: The human tumor clonogenic assay in human breast cancer. J Clin Oncol 3:92–97, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Braich, T.A., Salmon, S.E., Robertone, A. et al. Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma. Invest New Drugs 4, 269–274 (1986). https://doi.org/10.1007/BF00179595
Issue Date:
DOI: https://doi.org/10.1007/BF00179595